EPIX Therapeutics

EPIX Therapeutics is producer of the systems of radio-frequency kateterny ablation for patients with violations of a warm rhythm. The company was founded in the USA in 2007 and till August, 2018 Advanced Cardiac Therapeutic was called.

History

2019

Medtronic paid $316 million for EPIX Therapeutics purchase

At the end of June, 2019 Medtronic closed the transaction on purchase of EPIX Therapeutics and called the amount which was paid for this producer of tools for treatment of arrhythmia of heart — $316 million.

Medtronic purchased EPIX Therapeutics

At the end of January, 2019 Medtronic signed the final agreement about EPIX Therapeutics purchase. The acquired company will expand a portfolio of tools of Medtronic for treatment of patients with cardiac arrhythmia.

Flagman EPIX technology is the system of ablation DiamondTemp which represents the closed system with temperature monitoring allowing doctors to improve feedback coupling and control at accomplishment of the procedure. The company claims that the DiamondTemp system differs from other technologies of radio-frequency ablation thanks to the best temperature monitoring in real time. It allows to reduce duration of the procedure and to improve clinical outcomes.

Medtronic purchased the developer of tools for treatment of arrhythmia of heart

The DiamondTemp system received marking of CE in Europe in 2017, however in the USA was applied only within clinical trials. In it radio-frequency energy for creation of cicatricial fabric in heart is used. This device supplements cryoballoon technology of Medtronic which uses krioenerginny energy for isolation of pulmonary veins at violations of a rhythm of heart.

For use of the DiamondTemp system at patients the research DIAMOND-AF, registration of patients in which came to the end in October, 2018, was begun with symptomatic paroksizmalny FP in the USA. Besides, in 2019 the research DIAMOND-AF II in which the system effectiveness of DiamondTemp will be estimated at patients from persistiruyushchy FP will be conducted.

It is expected that the deal on sale of EPIX Therapeutics will be closed in the fourth financial quarter of Medtronic, i.e. from January 26 to April 26, 2019. Financial agreement details not of an obnardovana.^[1]

Notes